#SSc16 – Scleroderma News Top Articles Selection for the Congress
The 4th Systemic Sclerosis World Congress will take place in Lisbon, Portugal, from 18th to 20th February and Scleroderma News will be covering the whole event. Even though this is a systemic sclerosis (SSc) congress, a lot will be discussed about pulmonary arterial hypertension (PAH), which is considered a leading cause of mortality among systemic scleroderma patients.
Therefore, we decided to chose one article per satellite symposium that Scleroderma News team is planning to cover. Here are the articles:
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress.
A recent study published in the journal Arthritis Research & Therapy analyzed different prediction algorithms for the efficient diagnosis of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis.
Irving, Texas-based Reata Pharmaceuticals, Inc. announced initial data from the LARIAT (A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension) trial (ClinicalTrials.gov Identifier: NCT02036970), evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015 American College of Chest Physicians (CHEST), running from October 25 to 28 at the Palais des Congrès de Montrèal Convention Center.
Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind Phase 3 study developed in collaboration with GlaxoSmithKline (GSK). The study is entitled “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.”